Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1754-1761

  Liao, Bin Chi ^a   Lee, Jih Hsiang ^a   Lin, Chia Chi ^a,b   Chen, Ya Fang ^c   Chang, Chin Hao ^a   Ho, Chao Chi ^a   Shih, Jin Yuan ^a   Yu, Chong Jen ^a   Yang, James Chih Hsin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Department of Medical Imaging ^*  (United States)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Leptomeningeal carcinomatosis; Non small cell lung cancer; Prognosis; Whole brain radiation therapy

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; OSIMERTINIB; ROCILETINIB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOMATOUS MENINGITIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; EGFR GENE; FEMALE; GENDER; GENE; GENE MUTATION; HUMAN; LOCAL THERAPY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OMMAYA RESERVOIR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; SURVIVAL TIME; SYSTEMIC THERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84947915808     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000669     Document Type: Article

References (56)

1. Bruna J, González L, Miró J, et al. Leptomeningeal carcinomatosis. Cancer 2009;115:381-389.
2. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J Formos Med Assoc 2008;107:851-856.
3. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-2348.
4. Chamberlain MC. Neoplastic meningitis. Oncologist 2008;13:967-977.
5. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
9. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
11. Gow CH, Chien CR, Chang YL, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008;14:162-168.
12. So T, Inoue M, Chikaishi Y, Nose N, Sugio K, Yasumoto K. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today 2009;39:598-602.
13. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009;65:80-84.
14. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinibrefractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57; quiz 1 p following 57.
15. Xu Q, Chen X, Qian D, et al. Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer. Thorac Cancer 2014: in press.
16. Riess JW, Nagpal S, Iv M, et al. Prolonged survival of patients with nonsmall-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer 2014;15:202-206.
17. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in nonsmall-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-191.
18. Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012;77:134-139.
19. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-392.
20. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-385.
21. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998;37:271-284.
22. Gwak HS, Joo J, Kim S, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013;8:599-605.
23. Takenaka T, Yamagata M, Fukuda A, Sonoda T. Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib. BMJ Case Reports 2011;2011.
24. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-1419.
25. Wagner M, Besse B, Balleyguier C, Soria JC. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol 2008;3:677-679.
26. Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of nonsmall-cell lung cancer. Lung Cancer 2006;53:387-390.
27. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 2005;50:265-269.
28. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405.
29. Bruna J, González L, Miró J, et al. Leptomeningeal carcinomatosis. Cancer 2009;115:381-389.
30. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J Formos Med Assoc 2008;107:851-856.
31. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-2348.
32. Chamberlain MC. Neoplastic meningitis. Oncologist 2008;13:967-977.
33. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
34. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
35. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
36. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
37. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
38. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
39. Gow CH, Chien CR, Chang YL, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008;14:162-168.
40. So T, Inoue M, Chikaishi Y, Nose N, Sugio K, Yasumoto K. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today 2009;39:598-602.
41. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009;65:80-84.
42. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinibrefractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57; quiz 1 p following 57.
43. Xu Q, Chen X, Qian D, et al. Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer. Thorac Cancer 2014: in press.
44. Riess JW, Nagpal S, Iv M, et al. Prolonged survival of patients with nonsmall-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer 2014;15:202-206.
45. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in nonsmall-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-191.
46. Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012;77:134-139.
47. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-392.
48. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-385.
49. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 1998;37:271-284.
50. Gwak HS, Joo J, Kim S, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013;8:599-605.
51. Takenaka T, Yamagata M, Fukuda A, Sonoda T. Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib. BMJ Case Reports 2011;2011.
52. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-1419.
53. Wagner M, Besse B, Balleyguier C, Soria JC. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol 2008;3:677-679.
54. Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of nonsmall-cell lung cancer. Lung Cancer 2006;53:387-390.
55. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 2005;50:265-269.
56. Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399-405.